Popularization period: the first LASIK (IK, excimer in situ keratomileusis) surgery was successfully carried out in 1997 in China, LASIK surgery was developed on the basis of PRK, the surgery avoids the corneal epithelial overgrowth and corneal haze turbidity phenomenon after PRK surgery, and it is favored by myopia patients because of its wider scope of adaptation and more stable effect.
Enhancement: LASEK (EK for short, excimer laser subepithelial keratomileusis) is a brand new laser treatment myopia surgery for patients with thin corneas, high and ultra-high myopia that can not be corrected by LASIK, and after the surgery, it can solve the problem of aberration and glare for patients with ultra-high myopia, and the safety has been increased.LASEK is a new laser treatment myopia surgery to solve the problem of high and ultra-high myopia, and it is the first time to solve the problem of high and ultra-high myopia. LASEK is an effective refractive surgery method for patients with high myopia and insufficient corneal thickness, with minimal fluctuation in refraction and minimal refractive regression after surgery.
For more information about the origin of myopia surgery, you can consult Sigma Eye Hospital, Beijing Sigma Lin Shun Chao Eye Hospital (Sigma Eye) is a Beijing-Hong Kong medical cooperation ophthalmology specialty hospital, founded by ophthalmologist Lin Shun Chao, under the banner of the Sigma International Ophthalmology Medical Group.On January 15, 2018, the Group was officially listed on the stock market in China Hong Kong, with the stock code: 03309. HK. With the philosophy of "adhering to international standards, firming up the original heart of doctors, and upholding the quality of Sigma", Sigma Eye Hospital takes everything for the patients as the center, strengthens the medical quality standards, and emphasizes the quality of service.